Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 3/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 7/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653509 | 0.84 | ALK (0.59) | INSRALKIGF1RFLT3AURKA | |
| SCHEMBL652871 | 0.78 | ALPL (0.43) | RAB9ANPC1 | |
| SCHEMBL1335642 | 0.72 | IP6K1 (0.56) | HTR6RAB9ANPC1 | |
| SCHEMBL2910788 | 0.70 | INSR (0.48) | INSRALKIGF1RFLT3AURKA | |
| SCHEMBL2910310 | 0.70 | IGF1R (0.55) | INSRALKIGF1RFLT3AURKA | |
| SCHEMBL653322 | 0.69 | ALK (0.54) | INSRALKIGF1RFLT3AURKA | |
| SCHEMBL3881539 | 0.69 | AURKA (0.60) | INSRALKIGF1RFLT3AURKA | |
| SCHEMBL1894586 | 0.68 | IGF1R (0.51) | INSRALKIGF1RFLT3AURKA | |
| SCHEMBL30590422 | 0.67 | MAPT (0.55) | HTR6RAB9ANPC1 | |
| SCHEMBL2313915 | 0.67 | MAPT (0.55) | HTR6RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119641-B2 | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-21 | — | — | US | disclosed |
| EP-2051981-B1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-08-25 | — | — | EP | disclosed |
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-2051981-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-04-29 | — | — | EP | disclosed |
| WO-2007138017-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | IGF1R, CDK1, CDK15 | INSR 6/4885ALK 184/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.